罗沙司他治疗非透析慢性肾脏病患者贫血:DOLOMITES 3期随机对照研究
DOLOMITES研究是一项3期随机开放标签活性对照试验,纳入616例非透析慢性肾脏病贫血患者,比较罗沙司他与达依泊汀α的疗效。结果显示罗沙司他的血红蛋白应答率非劣于达依泊汀α(89.5% vs 78.0%,差值11.51%,95%CI 5.66-17.36%),且维持血红蛋白长达2年。罗沙司他在降低LDL和延迟首次静脉铁剂使用方面优于达依泊汀α,两组安全性和主要心血管事件无差异。
要点
- 罗沙司他血红蛋白应答率非劣于达依泊汀α,差值11.51%(95%CI 5.66-17.36%)。
- 罗沙司他可维持血红蛋白水平长达104周。
- 罗沙司他降低LDL和延迟首次静脉铁剂使用优于达依泊汀α。
核心结论
- 罗沙司他是治疗非透析慢性肾脏病患者贫血的可行选择,可维持血红蛋白水平长达104周。
研究设计与样本
- 随机、开放标签、活性对照3期研究,纳入616例非透析慢性肾脏病贫血患者,罗沙司他组323例,达依泊汀α组293例,治疗≤104周。
主要发现
- 罗沙司他血红蛋白应答率89.5%(256/286),达依泊汀α组78.0%(213/273),差值11.51%(95%CI 5.66-17.36%)。
- 罗沙司他维持血红蛋白长达2年。
- 罗沙司他在平均动脉压变化和高血压发生时间方面非劣于达依泊汀α。
- 罗沙司他在LDL变化和首次静脉铁剂使用时间方面优于达依泊汀α。
- 两组安全性和主要心血管事件(MACE)及MACE+复合终点无差异(MACE:0.81,95%CI 0.52-1.25,P=0.339;MACE+:0.90,95%CI 0.61-1.32,P=0.583)。
关键数值与推荐
- 血红蛋白目标范围10.0-12.0 g/dL,剂量滴定以纠正并维持血红蛋白在此范围。
- 主要终点为治疗前24周内血红蛋白应答率,定义:基线Hb>8.0 g/dL者Hb≥11.0 g/dL且较基线升高≥1.0 g/dL,或基线Hb≤8.0 g/dL者较基线升高≥2.0 g/dL,且未使用救援治疗。
- 非劣效界值为-15%。
临床怎么用
- 罗沙司他可考虑用于非透析慢性肾脏病贫血患者,以纠正并维持血红蛋白。
- 罗沙司他可能减少静脉铁剂使用并改善血脂,但需结合个体情况。
局限性
- 开放标签设计可能引入偏倚。
- 研究仅纳入非透析慢性肾脏病患者,结果不能外推至透析患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Roxadustat, an orally administered hypoxia-inducible factor prolyl hydroxylase inhibitor, is being evaluated for treatment of anaemia of chronic kidney disease (CKD). METHODS: This randomized, open-label, active-controlled Phase 3 study compared roxadustat versus darbepoetin alfa (DA) in non-dialysis-dependent (NDD) CKD patients with anaemia for ≤104 weeks. Doses were titrated to correct and maintain haemoglobin (Hb) within 10.0-12.0 g/dL. The primary endpoint was Hb response in the full analysis set, defined as Hb ≥11.0 g/dL and Hb change from baseline (BL; CFB) ≥1.0 g/dL in patients with BL Hb >8.0 g/dL or CFB ≥2.0 g/dL in patients with BL Hb ≤8.0 g/dL during the first 24 weeks of treatment without rescue therapy (non-inferiority margin, -15%). Key secondary endpoints included change in low-density lipoprotein (LDL), time to first intravenous (IV) iron use, change in mean arterial pressure (MAP) and time to hypertension occurrence. Adverse events were assessed. RESULTS: Of 616 randomized patients (roxadustat, 323; DA, 293), 424 completed treatment (roxadustat, 215; DA, 209). Hb response with roxadustat was non-inferior to DA (roxadustat: 256/286, 89.5% versus DA: 213/273, 78.0%, difference 11.51%, 95% confidence interval 5.66-17.36%). Roxadustat maintained Hb for up to 2 years. Roxadustat was non-inferior to DA for change in MAP and time to occurrence of hypertension and superior for change in LDL and time to first IV iron use. Safety profiles were comparable between groups. Findings suggest that there was no difference between groups regarding the composite endpoints major adverse cardiovascular events (MACEs) and MACE+ [MACE: 0.81 (0.52-1.25), P = 0.339; MACE+: 0.90 (0.61-1.32), P = 0.583]. CONCLUSIONS: Roxadustat is a viable option to treat anaemia in NDD CKD patients maintaining Hb levels for up to 104 weeks.
引用
- Barratt J, Andric B, Tataradze A, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021. PMID: 34077510. doi:10.1093/ndt/gfab191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。